Liver News and Research

RSS

Mercy Health Services deploys Wolters Kluwer Health's ProVation MD software

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Mercy Health Services has selected its ProVation MD software for gastroenterology procedure documentation and coding. The software will be deployed in the Institute for Digestive Health and Liver Disease at Mercy.

8 Jul 2010

Report shows more than one way to get rid of cholesterol

Many of us are simply overloaded with cholesterol, and now a report in the July issue of Cell Metabolism brings what might be good news: There is more than one way to get rid of that cholesterol, which can otherwise lead to atherosclerosis and heart disease.

8 Jul 2010

Report investigates clear cell ICC

Intrahepatic cholangiocarcinoma is a cancer of the bile duct in the liver. The clear cell subtype of ICC is a rare cancer; until now, only 8 cases have been reported. The number of reports is so small that a detail description of clear cell ICC is valuable.

8 Jul 2010

Common glucose test accurately predicts Type II adult-onset diabetes, study finds

A common test to diagnose gestational diabetes -- a temporary condition which can harm both mother and child if left untreated -- also has predictive power for Type II adult-onset diabetes, a new Tel Aviv University study finds.

8 Jul 2010

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a grant from the National Institute of Health (NIH) to support the development of defensin-mimetic antimicrobial compounds for the treatment of malaria.

7 Jul 2010

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.

7 Jul 2010

TWINCORE researchers develop new model approaches for HCV research

The hepatitis C virus is highly specialised. We humans are its natural hosts. The only other living organisms that could be infected with the hepatitis C virus in the lab are chimpanzees. Nevertheless it is - from the viewpoint of the virus - highly successful: around 170 million people are chronically infected with the virus. And with the chronic infection the risk of developing liver cancer also increases.

7 Jul 2010

New research shows cellular changes in fat tissue lead to type 2 diabetes

Cellular changes in fat tissue-not the immune system-lead to the "hyperinflammation" characteristic of obesity-related glucose intolerance and type 2 diabetes, according to new research from the University of Cincinnati.

7 Jul 2010

US WorldMeds launches Revonto for malignant hyperthermia

US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH). The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear. Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

7 Jul 2010

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

7 Jul 2010

First Australian intestinal transplant

Mr. Brendan Cole, 32 became the first recipient of a successful intestinal transplant in Australia. Last Friday he had his intestines and organs removed from his abdomen that followed a 12 hour operation at Austin Health.

4 Jul 2010

Transplanted beta cells protect themselves by adapting to their new homes

For transplanted beta cells, life is tough. Not only are the insulin-producing cells in a stranger's body, tucked into the liver rather than the pancreas, they are a bit short on oxygen and blood, and they are often exposed to raised levels of glucose.

3 Jul 2010

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Tacrolimus 5 mg capsules, the generic equivalent to Astellas' Prograf® capsules.

2 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

Virus related to hepatitis C discovered in Asian bats

Viral hepatitis affects more than 500 million people worldwide and is a cause of liver failure and liver cancer. While vaccines are available for hepatitis A and B, this is not the case for hepatitis C, which affects as much as two percent of the population in the U.S. Scientists today are reporting discovery of a virus related to hepatitis C in Asian bats, which may provide insights into the origins of the hepatitis C virus and into the mechanisms by which infectious diseases move from other species to humans.

2 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Researchers identify a set of molecular signatures for biliary atresia

Researchers have identified a set of "molecular signatures" for biliary atresia - the most common diagnosis leading to liver transplant in children - that can help identify the progression of disease at diagnosis and predict clinical outcomes.

1 Jul 2010

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Fero Industries, Inc. is pleased to announce that it has closed the acquisition of certain intellectual property and other associated rights related to the production, marketing, and distribution of Sucanon, a treatment for Type II diabetes.

1 Jul 2010

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Raptor Pharmaceutical Corp., announced that it has entered into an exclusive agreement with Uni Pharma Co., Ltd. to commercialize Convivia™, Raptor's proprietary oral formulation of 4-methylpyrazole, in Taiwan.

30 Jun 2010

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

Mirna Therapeutics announced today publication of new results in the journal Cancer Research demonstrating proof of concept that the systemic delivery of tumor suppressor microRNAs (miRNA) inhibits tumor growth by restoring the proper regulatory pathways required for cell cycle arrest and apoptosis.

30 Jun 2010

Liver News and Research

Mercy Health Services deploys Wolters Kluwer Health's ProVation MD software

Report shows more than one way to get rid of cholesterol

Report investigates clear cell ICC

Common glucose test accurately predicts Type II adult-onset diabetes, study finds

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

Alnylam Pharmaceuticals initiates dosing in Phase I human clinical study with ALN-TTR01

TWINCORE researchers develop new model approaches for HCV research

New research shows cellular changes in fat tissue lead to type 2 diabetes

US WorldMeds launches Revonto for malignant hyperthermia

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

First Australian intestinal transplant

Transplanted beta cells protect themselves by adapting to their new homes

Watson Laboratories receives FDA approval for Tacrolimus ANDA

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Virus related to hepatitis C discovered in Asian bats

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Researchers identify a set of molecular signatures for biliary atresia

Fero Industries closes acquisition of rights related to production, marketing and distribution of Sucanon

Raptor partners with Uni Pharma to commercialize Convivia in Taiwan

Data published in Cancer Research demonstrates proof of concept for Mirna's tumor suppressor miRNAs

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News